Journal of Hepatology
Volume 49, Issue 2 , Pages 175-183 , August 2008

Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France

  • Sylvie Deuffic-Burban

      Affiliations

    • CTRS-INSERM U795, CHRU Lille, Lille, France
    • LEM-CNRS, Université Catholique de Lille, 41 rue du Port, Lille 59046, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 3 20 13 40 62; fax: +33 3 20 13 40 70.
    • ,
  • Pierre Deltenre

      Affiliations

    • Service d’Hépato-Gastroentérologie, Hôpital de Jolimont, Haine-Saint-Paul, Belgium
    • Service d’Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France
    • ,
  • Alexandre Louvet

      Affiliations

    • CTRS-INSERM U795, CHRU Lille, Lille, France
    • Service d’Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France
    • ,
  • Valérie Canva

      Affiliations

    • Service d’Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France
    • ,
  • Sebastien Dharancy

      Affiliations

    • CTRS-INSERM U795, CHRU Lille, Lille, France
    • Service d’Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France
    • ,
  • Antoine Hollebecque

      Affiliations

    • CTRS-INSERM U795, CHRU Lille, Lille, France
    • Service d’Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France
    • ,
  • Jeanne Boitard

      Affiliations

    • CTRS-INSERM U795, CHRU Lille, Lille, France
    • Service d’Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France
    • ,
  • Jean Henrion

      Affiliations

    • Service d’Hépato-Gastroentérologie, Hôpital de Jolimont, Haine-Saint-Paul, Belgium
    • ,
  • Yazdan Yazdanpanah

      Affiliations

    • LEM-CNRS, Université Catholique de Lille, 41 rue du Port, Lille 59046, France
    • Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France
    • EA 2694, Faculté de Médecine de Lille, Lille, France
    • ,
  • Philippe Mathurin

      Affiliations

    • CTRS-INSERM U795, CHRU Lille, Lille, France
    • Service d’Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France

Received 10 September 2007 ,Revised 26 March 2008 ,Accepted 14 April 2008.

References 

  1. Marcellin P, Pequignot F, Delarocque-Astagneau E, Ganne N, Hillon P, Bovet M, et al. Evidence for high rates of HCV and HBV related mortality in France: a large-scale national survey. J Hepatol. 2006;44:S174
  2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  3. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  4. Manns M, McHutchinson JG, Gordon S, Rustgi V, Shiffman ML, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  5. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis: effects of dose and duration. Hepatology. 1996;24:778–789
  6. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313
  7. Dubois F, Desenclos JC, Mariotte N, Goudeau A The Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology. 1997;25:1490–1496
  8. Meffre C, Le Strat Y, Delarocque-Astagneau E, Meyer J, Coste D, Steinmetz J. Prevalence of hepatitis C in France, 2003–2004. 41st Annual meeting of the European Association for the Study of the Liver; 2006 April 26–30; Vienna, Austria; 2006. J Hepatol 2006;44:S22.
  9. Fartoux L, Degos F, Trepo C, Goria O, Cales P, Tran A, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol. 2007;5:502–507
  10. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870–1875
  11. Benvegnù L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998;83:901–909
  12. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587
  13. Cammà C, Giunta M, Andreone P, Craxı` A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593–602
  14. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409–414
  15. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998;27:914–919
  16. Corrao G, Zambon A, Torchio P, Arico S, LaVecchia C, diOrio F. Attributable risk for symptomatic liver cirrhosis in Italy. J Hepatol. 1998;28:608–614
  17. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004;39:826–834
  18. Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730–1735
  19. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832
  20. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001;34:730–739
  21. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997;26:485–490
  22. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805–809
  23. Kim WR, Gross JB, Poterucha JJ, Locke GR, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology. 2001;33:201–206
  24. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology. 1999;29:1596–1601
  25. Deuffic-Burban S, Wong JB, Valleron A-J, Costagliola D, Delfraissy JF, Poynard T. Comparing the Public Health burden of chronic hepatitis C and HIV infection in France. J Hepatol. 2004;40:319–326
  26. Groupe d’experts. Alcool – Dommages sociaux, abus et dépendances. Paris: Expertise Collective – Les Editions INSERM; 2003.
  27. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat. 1999;6:435–443
  28. Pagliaro L, Peri V, Linea C, Cammà C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Italian J Gastroenterol Hepatol. 1999;31:28–44
  29. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20
  30. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435–1440
  31. Degos F, Christidis C, Ganne-Carrié N, Farmachidi J-P, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–136
  32. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231
  33. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62–65
  34. Bourliere M, Ouzan D, Rosenheim M, Doffoel M, Marcellin P, Pawlotsky JM, et al. Efficacy of peginterferon alpha-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study. Hepatology. 2007;46:366A
  35. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492
  36. Schalm SW, Weiland O, Hansen BE, Milella M, Lai FY, Hollander A, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology. 1999;117:408–413
  37. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015–1023
  38. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200–207
  39. Fong KW, Jefferson TH, Suyehiro T, Walton L. SLATEC Common Mathematical Library; 1993. Available from http://www.netlib.org/slatec/guide.
  40. Marquardt D. An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math. 1963;11:431–441
  41. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006;368:938–945
  42. Neal KR on behalf of the Trent Hepatitis C Study Group. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut. 2007;56:1098–1104
  43. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10–12, 2002). Gastroenterology 2002;123:2082–2099.

☆ Dr. Deuffic-Burban received an unrestricted grant from Roche Laboratories, France to conduct this study. The other authors do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00294-8

doi: 10.1016/j.jhep.2008.04.012

Journal of Hepatology
Volume 49, Issue 2 , Pages 175-183 , August 2008

Article Tools

* Image Usage & Resolution